drugset / Trial / NCT06075030

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

NCT06075030

Phase 2 Not yet recruiting 36 enrolled Kind Pharmaceuticals LLC
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

Timeline

Start
2027-12
Primary completion
2027-12
Completion
2028-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AND017 Unknown Oral